La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Marksans Pharma Crescita futura

Future criteri di controllo 4/6

Marksans Pharma prevede che gli utili e i ricavi cresceranno rispettivamente di 20.8% e 16.1% all'anno. Si prevede che l'EPS crescerà di 20.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 17.6% in 3 anni.

Informazioni chiave

21.2%

Tasso di crescita degli utili

21.2%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	18.0%
Tasso di crescita dei ricavi	16.3%
Rendimento futuro del capitale proprio	18.1%
Copertura analitica	Low
Ultimo aggiornamento	05 Sep 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06

These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Nov 19

Previsioni di crescita degli utili e dei ricavi

NSEI:MARKSANS - Stime future degli analisti e dati finanziari passati (INR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2027	35,690	5,974	4,354	N/A	2
3/31/2026	31,110	4,823	3,460	N/A	3
3/31/2025	26,418	3,859	2,025	N/A	3
6/30/2024	22,680	3,338	N/A	N/A	N/A
3/31/2024	21,774	3,137	216	2,304	N/A
12/31/2023	21,034	3,164	N/A	N/A	N/A
9/30/2023	19,971	2,965	894	2,528	N/A
6/30/2023	19,184	2,743	N/A	N/A	N/A
3/31/2023	18,521	2,663	1,838	2,374	N/A
12/31/2022	17,842	2,123	N/A	N/A	N/A
9/30/2022	16,670	2,004	972	1,286	N/A
6/30/2022	15,756	1,847	N/A	N/A	N/A
3/31/2022	14,908	1,868	529	993	N/A
12/31/2021	14,069	2,367	N/A	N/A	N/A
9/30/2021	14,026	2,473	883	1,336	N/A
6/30/2021	14,064	2,518	N/A	N/A	N/A
3/31/2021	13,762	2,385	1,322	1,786	N/A
12/31/2020	13,817	2,018	N/A	N/A	N/A
9/30/2020	13,142	1,724	1,839	2,478	N/A
6/30/2020	12,203	1,476	N/A	N/A	N/A
3/31/2020	11,344	1,208	1,734	2,333	N/A
12/31/2019	10,463	879	N/A	N/A	N/A
9/30/2019	9,972	834	66	416	N/A
6/30/2019	10,099	780	N/A	N/A	N/A
3/31/2019	10,001	804	142	274	N/A
12/31/2018	9,523	666	N/A	N/A	N/A
9/30/2018	9,223	582	N/A	N/A	N/A
6/30/2018	9,272	463	N/A	N/A	N/A
3/31/2018	9,127	358	N/A	501	N/A
12/31/2017	8,918	343	N/A	N/A	N/A
9/30/2017	8,949	275	N/A	N/A	N/A
6/30/2017	8,015	187	N/A	N/A	N/A
3/31/2017	7,672	113	N/A	141	N/A
12/31/2016	7,926	70	N/A	N/A	N/A
9/30/2016	7,948	136	N/A	N/A	N/A
6/30/2016	8,699	481	N/A	N/A	N/A
3/31/2016	8,933	785	N/A	308	N/A
12/31/2015	8,536	1,093	N/A	N/A	N/A
9/30/2015	8,495	1,191	N/A	N/A	N/A
6/30/2015	8,045	1,154	N/A	N/A	N/A
3/31/2015	7,967	1,094	N/A	1,545	N/A
12/31/2014	7,850	950	N/A	N/A	N/A
9/30/2014	7,405	897	N/A	N/A	N/A
6/30/2014	6,914	786	N/A	N/A	N/A
3/31/2014	6,300	719	N/A	648	N/A
12/31/2013	5,950	1,020	N/A	N/A	N/A
9/30/2013	5,406	877	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di MARKSANS ( 20.8% all'anno) è superiore al tasso di risparmio ( 6.7% ).

Guadagni vs Mercato: Si prevede che gli utili di MARKSANS ( 20.8% all'anno) cresceranno più rapidamente del mercato Indian ( 16.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di MARKSANS cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di MARKSANS ( 16.1% all'anno) crescerà più rapidamente del mercato Indian ( 10% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MARKSANS ( 16.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di MARKSANS sarà basso tra 3 anni ( 17.6 %).

Marksans Pharma Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Marksans Pharma Limited Approves Dividend for the Year Ended March 31, 2024

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Upcoming dividend of ₹0.60 per share

Insufficient new directors

Now 21% overvalued after recent price rise

Successful Closure of US FDA Inspection At Marksans Pharma's Manufacturing Facility Located At Verna, Goa

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024

First quarter 2025 earnings released: EPS: ₹1.96 (vs ₹1.52 in 1Q 2024)

Marksans Pharma Limited to Report Q1, 2025 Results on Aug 13, 2024

Now 20% overvalued after recent price rise

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Investor sentiment improves as stock rises 18%

Whole-time Director recently bought ₹6.9m worth of stock

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Full year 2024 earnings: EPS misses analyst expectations

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24

Marksans Pharma Limited to Report Q4, 2024 Results on May 30, 2024

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% overvalued after recent price rise

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Marksans Pharma Limited to Report Q3, 2024 Results on Feb 13, 2024

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹1.84 (vs ₹1.52 in 2Q 2023)

Marksans Pharma Limited to Report Q2, 2024 Results on Nov 09, 2023

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets

Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23

Full year 2023 earnings released: EPS: ₹6.39 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Investor sentiment improves as stock rises 16%

Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg

Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023

Full year 2023 earnings released: EPS: ₹6.41 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹1.56 (vs ₹1.20 in 3Q 2022)

Marksans Pharma Limited to Report Q3, 2023 Results on Feb 13, 2023

Marksans Pharma Limited announced that it has received funding from OrbiMed Asia IV Mauritius FVCI Limited

Second quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.11 in 2Q 2022)

Marksans Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022

Marksans Pharma Limited (BSE:524404) entered into a Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited.

Marksans Pharma Limited Declares Dividend, Payable on or After 20 September 2022

Upcoming dividend of ₹0.25 per share

Full year 2022 earnings released: EPS: ₹4.56 (vs ₹5.83 in FY 2021)

Marksans Pharma Limited to Report Q1, 2023 Results on Aug 13, 2022

Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022

Marksans Pharma Limited Announces US FDA Approval for Pregabalin Capsules

Marksans Pharma Limited (BSE:524404) announces an Equity Buyback for INR 600 million worth of its shares.

Investor sentiment improved over the past week

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Marksans Pharma Limited (BSE:524404) completed the acquisition of Access Healthcare for Medical Products LLC.

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Fiscal Year 2022 Results on May 30, 2022

Marksans Pharma Limited (BSE:524404) has signed agreement to acquire share capital of Access Healthcare for Medical Products LLC for AED 13 million.

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Q3, 2022 Results on Feb 11, 2022

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Second quarter 2022 earnings released: EPS ₹1.11 (vs ₹1.21 in 2Q 2021)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Upcoming dividend of ₹0.25 per share

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

First quarter 2022 earnings released: EPS ₹1.51 (vs ₹1.20 in 1Q 2021)

Investor sentiment deteriorated over the past week

Marksans Pharma Limited announced that it has received INR 930.999994 million in funding from OrbiMed Asia IV Mauritius FVCI Limited and other investor

Marksans Pharma Limited announced that it expects to receive INR 930.999994 million in funding

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Investor sentiment improved over the past week